Abstract 1707P
Background
Rising cancer drug prices pose a challenge for patients and healthcare systems in the US. Whilst prices are routinely assigned to a drug’s original indication receiving US Food and Drug Administration (FDA) approval, the influence of supplemental indication approvals on prices remains uncertain. This study identifies and quantifies factors associated with cancer drug prices, distinctly analyzing original and supplemental indications.
Methods
Clinical trial evidence supporting each indication’s FDA approval was collected from the Drugs@FDA database (2003-2022). Disease incidence and disability-adjusted life years (DALYs) were obtained from the Global Burden of Disease study. Indication-specific monthly treatment costs were calculated for patients covered under Medicare Part B and D. The association between log-prices and collected variables was assessed in univariate regression analyses.
Results
We identified 145 drugs approved across 373 cancer indications. Drugs were priced at $24,444 per month on average (median $16,013; IQR 14,648 to 22,348). For original indications, prices were only weakly correlated to improvements in overall survival (β=0.28, 95%CI 0.02 to 0.54, p=0.037) and progression-free survival (β=0.16, 95%CI 0.07 to 0.25, p=0.001). Original indications’ prices were: (1) negatively associated with disease incidence (β=-0.21, 95%CI -0.28 to -0.13, p<0.001) and prevalence; (2) positively correlated for first-in-class drugs (26%, 95%CI -1 to 60, p=0.057), gene & cell therapies (176%, 95%CI 79 to 324, p<0.001), hematologic cancers (52%, 95%CI 28 to 106, p<0.001), and severe diseases with substantial unmet needs (6% per DALY, 95%CI 3 to 8, p<0.001); and (3) negatively correlated to indications with randomized controlled phase III trials. Prices were only poorly associated with supplemental indications’ efficacy, clinical evidence, and epidemiology.
Conclusions
Cancer drug prices are set based on the original indication’s characteristics, thereby omitting the value of supplemental indications. Indication-specific pricing, coverage, and reimbursement policies considering each indication’s safety, efficacy, innovativeness, and unmet needs are necessary to align a drug’s value and price.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1757P - A real-world evaluation of the effectiveness of thermogram along with clinical breast examination in community-based breast cancer screening program
Presenter: Rahul Ravind
Session: Poster session 23
1758P - Body composition meets precision medicine: The prognostic value of sarcopenia in patients (pt) treated with Molecularly Targeted Agents (MTA)
Presenter: Cinta Hierro
Session: Poster session 23
1760P - Systematic review of quality of life (QoL) inclusion among endpoints, reporting and impact of QoL results in phase III non-inferiority trials of systemic treatments in oncology
Presenter: Jessica Paparo
Session: Poster session 23
1761P - Incidence of herpes zoster in cancer patients in Europe: A systematic review
Presenter: Inga Posiuniene
Session: Poster session 23
1762P - Are published data up-to-date? Analysis of time to publication in major oncological journals
Presenter: Pawel Sobczuk
Session: Poster session 23
1763P - The challenge for Cancer Trials Ireland (CTI) to sponsor NCI and non-EU sponsored trials in the EU
Presenter: Eibhlin Mulroe
Session: Poster session 23
1886P - Pembrolizumab and denosumab in clear cell renal cell carcinoma (ccRCC): A phase II trial (KeyPAD, ANZUP1601)
Presenter: Craig Gedye
Session: Poster session 23
1887P - Adjuvant everolimus (EVE) in patients (pts) with completely resected very high-risk renal cell cancer (RCC) and clear cell histology: Results from the phase III SWOG S0931 (EVEREST) trial
Presenter: Primo Lara
Session: Poster session 23
1888P - 24-month follow up of durvalumab and savolitinib combination in MET-driven clear cell and non-clear cell renal cancer
Presenter: Francesca Jackson-Spence
Session: Poster session 23